ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02207530
Recruitment Status : Active, not recruiting
First Posted : August 4, 2014
Results First Posted : June 18, 2018
Last Update Posted : September 25, 2018
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR

Condition or disease Intervention/treatment Phase
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck Drug: MEDI4736 Phase 2

Detailed Description:
This is a phase II, multi-center, single-arm, global study of MEDI4736 monotherapy in patients with PD-L1 positive recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN), who have progressed during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Actual Study Start Date : October 24, 2014
Actual Primary Completion Date : September 26, 2016
Estimated Study Completion Date : September 28, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: MEDI4736
MEDI4736 monotherapy
Drug: MEDI4736
MEDI4736 monotherapy




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 12 months ]

    Objective response rate (per RECIST 1.1 as assessed by blinded independent central review [BICR]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR.

    Response Evaluation Criteria in Solid Tumors [RECIST] 1.1. criteria are: Complete response [CR] = disappearance of all target lesions since baseline; and partial response [PR] = at least a 30% decrease in the sum of the diameters of target lesions.



Secondary Outcome Measures :
  1. Best Objective Response [ Time Frame: 12 months ]

    Best objective response based on BICR assessments according to RECIST v1.1. Response required confirmation after 4 weeks.

    Unconfirmed complete (CR) or partial response (PR) refers to CR or PR achieved but either no confirmation assessment was performed or a confirmation assessment was performed but response was not confirmed.


  2. Duration of Response- Participants Remaining in Response [ Time Frame: 12 months ]

    Participants remaining in response - based on BICR assessments according to RECIST v1.1.

    An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.


  3. Duration of Response [ Time Frame: 12 months ]

    Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1.

    Duration of response was the time from the first documentation of complete or partial response until the date of progression (which was subsequently confirmed), death, or the last evaluable RECIST assessment for patients that did not progress.

    An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.


  4. Time to Onset of Response From First Dose [ Time Frame: 12 months ]
    Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1

  5. Disease Control at 6 Months [ Time Frame: 6 months ]

    Disease control (DCR) at 6 months based on BICR assessments according to RECIST v1.1.

    DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD):

    • Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following the start of study treatment.
    • Method 2: Patients who had a best objective response of CR or PR within 24 weeks or had demonstrated SD for a minimum interval of 16 weeks following the start of study treatment.

  6. Progression-free Survival [ Time Frame: 12 months ]

    Progression status based on BICR assessments according to RECIST v1.1 at time of PFS analysis.

    Progression was defined as the time from the date of first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression.


  7. Overall Survival (OS) [ Time Frame: 12 months ]
    Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status, or who were lost to follow-up.

  8. Quality of Life [ Time Frame: 12 months ]

    Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires:

    • The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3.
    • Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H&N35.

    Function or global health status/quality of life improvement was defined as patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (an increase from baseline score ≥10). Symptom improvement was defined as 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10).

    Scale improvement was defined as patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Written informed consent obtained from the patient/legal representative
  • Histologically confirmed recurrent or metastatic SCCHN
  • Tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent.
  • Written consent to provide newly acquired tumor tissue (preferred) or archival tissue for the purpose of establishing PD-L1 status.
  • Confirmed PD-L1-positive SCCHN by Ventana SP263 assay
  • WHO/ECOG performance status of 0 or 1
  • At least 1 measurable lesion at baseline
  • No prior exposure to immune-mediated therapy
  • Adequate organ and marrow function
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test.

Exclusion Criteria:

  • Histologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck
  • Received more than 1 systematic palliative regimen for recurrent or metastatic disease
  • Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment
  • Prior randomization or treatment in a previous MEDI4736 and/or tremelimumab clinical study regardless of treatment arm assignment or receipt of any investigational anticancer therapy within 28 days or 5 half-lives
  • Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment
  • Major surgical procedure within 28 days prior to the first dose of Investigational Product
  • Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736
  • History of allogeneic organ transplantation
  • Active or prior documented autoimmune or inflammatory disorders;
  • Uncontrolled intercurrent illness
  • Another primary malignancy
  • Patients with history of brain metastases, spinal cord compression, or leptomeningeal carcinomatosis
  • History of active primary immunodeficiency
  • Known history of previous tuberculosis
  • Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
  • Pregnant or breast-feeding female patients
  • Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the IP or interpretation of patient safety or study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02207530


  Show 108 Study Locations
Sponsors and Collaborators
AstraZeneca
PRA Health Sciences
Investigators
Principal Investigator: Dan Paul Zandberg, MD International Coordinating Investigator
Study Director: Magdalena Wrona Medical Scientist AstraZeneca Magdalena.Wrona@astrazeneca.com

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02207530     History of Changes
Other Study ID Numbers: D4193C00001
First Posted: August 4, 2014    Key Record Dates
Results First Posted: June 18, 2018
Last Update Posted: September 25, 2018
Last Verified: September 2018

Keywords provided by AstraZeneca:
Head and neck cancer; SCCHN

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs